Endocrine Abstracts

Introduction: Generously supported by IPSEN)-->Hyperprolactinemia (HPRL) is associated with an impaired metabolic profile, particularly in patients with hypogonadism. This study aimed to: i) investigate the effects of short and long treatment with cabergoline (CAB) on the prevalence of metabolic syndrome (MS) and insulin sensitivity and ii) to evaluate the impact of gonadal function on metabolic changes, in male patients with HPRL.</...

Aim: To evaluate the effects of short and long-term treatment with PEG on rhythm disturbances in a cohort of acromegalic patients resistant to long-term high-dose therapy with SA.Patients and methods: Thirteen patients (4 M, 9 F, aged 44±9.25 years) entered the study. All patients started PEG at initial dose of 10 mg daily, then increased of 5 mg every 6 weeks on the basis of IGF1 levels, until IGF1 normalisation or until the achievement of the maxi...

The GH-receptor antagonist PEG, used as monotherapy or in combination to SA, has been demonstrated to normalize IGF1 levels in up to 90% of acromegalic patients after unsuccessful surgery and/or radiotherapy and resistant to conventional SA treatment. The aim of this study is to evaluate the efficacy and safety of combined treatment with SA plus PEG in a cohort of acromegalic patients resistant to conventional SA therapy. Thirty-two acromegalic patients (17 M, 15 F, age 39.6&#...

Background: Thyroid function, insulin resistance, serum lipid, C-reactive protein (CRP) and homocysteine are associated with an increased cardiovascular risk in patients with autoimmune thyroiditis (AIT).Objective: To evaluate the interrelations between thyroid function, insulin resistance, serum lipid concentrations, CRP and homocysteine in patients with AIT and subclinical hypothyroidism.Subjects and methods: We recorded thyroid ...

Background: Autoimmune thyroiditis (AIT) is associated with increased risk of cardiovascular disease.Objective: To evaluate the interrelationships between insulin resistance (IR) and other cardiovascular risk factors, such as high sensitivity CRP (C reactive protein) and homocysteine in patients with AIT.Patients and methods: We analysed thyroid function, anti-thyroid antibodies, BMI, indices of IR, such as HOMA-IR, HISI (Hepatic I...

Background: Thyroid dysfunction and lipid profile are associated with cardiovascular disease in patients with autoimmune thyroiditis (AIT).Objective: To evaluate the association between thyroid function, lipid concentrations, C-reactive protein (CRP) and homocysteine in patients with AIT.Patients and methods: We assessed thyroid function tests, BMI, total cholesterol (TC), HDL-cholesterol, LDL-cholesterol, triglycerides (TG), apoli...

Aims: To examine whether treated autoimmune thyroiditis (AIT) and Graves’ disease (GD) are associated with increased cardiovascular risk factors.Patients and methods: We analysed the levels of total cholesterol (TC), HDL, LDL, triglycerides (TG), ApoB, ApoA1, Lp[a], homocysteine, CRP, folic acid and vitamin B12 in 50 patients with GD and in 130 patients with AIT, after normalization of thyroid function. Patients with GD were treated with propylthiou...

Objective: The aim of this study was to examine the hypothesis that thyroid function, in euthyroid subjects with autoimmune thyroiditis (AIT), is associated with insulin resistance, serum lipid concentrations, and other cardiovascular (CV) risk factors. Subjects and Methods: We recorded thyroid function tests, BMI, insulin resistance markers comprising the Homeostasis Model Assessment for insulin resistance (HOMA-IR), the Quantitative Insulin Sensitivity Check Index (QUICKI), ...

The aim of the present study was to evaluate cardiac valve insufficiency prevalence after 12-month combined treatment with somatostatin analogues (SA) and CAB in acromegalic patients partially responsive to high-dose and long-term SA monotherapy. Twenty-four patients entered the study. A standard echocardiography was performed in all patients at diagnosis, after high-dose and long-term SA therapy and 12 months after CAB addition to SA to evaluate ejection fraction (EF) and mit...

Therapy with labeled somatostatin analogues is the modern approach to patients with disseminated or unresectable NETs expressing somatostatin receptors (SSTR). Octreotate is the somatostatin analogue with high affinity to SSTR type 2, most commonly present in NETs. The aim of the study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in NETs....